The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytes

Background & Aims: Atezolizumab plus bevacizumab (Atez/Bev) improves prognosis in advanced hepatocellular carcinoma, but its mechanisms remain unclear. This study aims to identify predictive biomarkers through a comprehensive analysis of the tumor microenvironment. Methods: Biopsy samples from 9...

全面介紹

書目詳細資料

Principais autores:	Hiroaki Kanzaki, Takamasa Ishino, Sadahisa Ogasawara, Takahiro Tsuchiya, Makoto Fujiya, Midori Sawada, Ryo Izai, Teppei Akatsuka, Chihiro Miwa, Takuya Yonemoto, Sae Yumita, Miyuki Nakagawa, Ryuta Kojima, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Naoya Kanogawa, Masato Nakamura, Takayuki Kondo, Shingo Nakamoto, Tsukasa Takayashiki, Yuka Takano, Kaho Takata, Jason Lin, Masahito Kawazu, Jun-ichiro Ikeda, Masayuki Ohtsuka, Yujin Hoshida, Mina Komuta, Yosuke Togashi
格式:	Artigo
語言:	Inglês
出版:	Elsevier 2025-12-01
叢編:	JHEP Reports
主題:	atezolizumab bevacizumab immunotherapy hepatocellular carcinoma tumor-infiltrating lymphocyte tumor microenvironment
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S2589555925002964
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!